Protagonist Therapeutics Inc (PTGX) financials
Protagonist Therapeutics revenue and earnings by year
Protagonist Therapeutics's revenue was $46.0 million in the fiscal year to December 31, 2025, down 89.4% from the year before. Net income was -$130 million, -282.8% of revenue. Since the fiscal year to December 31, 2017, revenue has grown 10.9% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 9 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46 | 434 | 60 | 27 | 27 | 29 | 0 | 31 | 20 |
| Revenue growth | -89.4% | 624.1% | 125.7% | -2.8% | -4.4% | 12293.1% | -99.3% | 54.1% | — |
| Operating income | -158 | 253 | -94 | -131 | -126 | -65 | -81 | -42 | -38 |
| Operating margin | -343.6% | 58.2% | -156.1% | -494.2% | -460.0% | -225.4% | -34857.6% | -136.7% | -188.9% |
| Net income | -130 | 275 | -79 | -127 | -126 | -66 | -77 | -39 | -37 |
| Net margin | -282.8% | 63.3% | -131.6% | -479.3% | -458.9% | -231.1% | -33414.3% | -125.9% | -184.2% |
| Diluted EPS | -$2.05 | $4.23 | -$1.39 | -$2.60 | -$2.71 | -$1.99 | -$2.99 | -$1.74 | -$2.10 |
| Free cash flow | 56 | 183 | -71 | -109 | -109 | -73 | -42 | -50 | 3 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open PTGX in Markets.
See also: PTGX valuation and P/E history · PTGX returns
No forecast, no recommendation. This page describes Protagonist Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.